Overview

Marimastat Following Chemotherapy in Treating Patients With Small Cell Lung Cancer

Status:
Completed
Trial end date:
2008-12-15
Target enrollment:
Participant gender:
Summary
RATIONALE: Marimastat may stop the growth of lung cancer by stopping blood flow to the tumor. It is not yet known if marimastat is an effective treatment for small cell lung cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of marimastat with a placebo following chemotherapy in treating patients who have small cell lung cancer.
Phase:
Phase 3
Details
Lead Sponsor:
NCIC Clinical Trials Group
Treatments:
Marimastat